Analysis of survival by tumor response: have we learnt any better?

被引：9

作者：

Ihorst, Gabriele ^{[1
]}

Waldschmidt, Johannes ^{[2
]}

Schumacher, Martin ^{[3
]}

Waesch, Ralph ^{[2
]}

Engelhardt, Monika ^{[1
]}

机构：

[1] Univ Med Ctr Freiburg, Ctr Clin Trials, Freiburg, Germany

[2] Univ Med Ctr Freiburg, Dept Hematol & Oncol, D-79106 Freiburg, Germany

[3] Univ Freiburg, Dept Med Biometry & Stat IMBI, D-79106 Freiburg, Germany

来源：

ANNALS OF HEMATOLOGY | 2015年 / 94卷 / 09期

关键词：

MULTIPLE-MYELOMA; RECOMMENDATIONS;

D O I：

10.1007/s00277-015-2426-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1615 / 1616

页数：2

共 10 条

[1] Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables [J].

Anderson, James R. ;

Cain, Kevin C. ;

Gelber, Richard D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) :3913-3915

[2] ANALYSIS OF SURVIVAL BY TUMOR RESPONSE [J].

ANDERSON, JR ;

CAIN, KC ;

GELBER, RD .

JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) :710-719

[3] Survival analysis in hematologic malignancies: recommendations for clinicians [J].

Delgado, Julio ;

Pereira, Arturo ;

Villamor, Neus ;

Lopez-Guillermo, Armando ;

Rozman, Ciril .

HAEMATOLOGICA, 2014, 99 (09) :1410-1420

[4]

Engelhardt M, 2014, RECENT RESULTS CANC, V201, P359, DOI 10.1007/978-3-642-54490-3_22

[5] European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma [J].

Engelhardt, Monika ;

Terpos, Evangelos ;

Kleber, Martina ;

Gay, Francesca ;

Waesch, Ralph ;

Morgan, Gareth ;

Cavo, Michele ;

van de Donk, Niels ;

Beilhack, Andreas ;

Bruno, Benedetto ;

Johnsen, Hans Erik ;

Hajek, Roman ;

Driessen, Christoph ;

Ludwig, Heinz ;

Beksac, Meral ;

Boccadoro, Mario ;

Straka, Christian ;

Brighen, Sara ;

Gramatzki, Martin ;

Larocca, Alessandra ;

Lokhorst, Henk ;

Magarotto, Valeria ;

Morabito, Fortunato ;

Dimopoulos, Meletios A. ;

Einsele, Hermann ;

Sonneveld, Pieter ;

Palumbo, Antonio .

HAEMATOLOGICA, 2014, 99 (02) :232-242

[6] Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses [J].

Haas, P. S. ;

Denz, U. ;

Ihorst, G. ;

Engelhardt, M. .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 80 (04) :303-309

[7] Preclinical models of multiple myeloma: a critical appraisal [J].

Schueler, Julia ;

Ewerth, Daniel ;

Waldschmidt, Johannes ;

Waesch, Ralph ;

Engelhardt, Monika .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 :S111-S123

[8] Surviving survival analysis [J].

Szydlo, RM .

BONE MARROW TRANSPLANTATION, 2001, 28 (10) :907-907

[9] Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization [J].

Udi, Josefina ;

Schueler, Julia ;

Wider, Dagmar ;

Ihorst, Gabriele ;

Catusse, Julie ;

Waldschmidt, Johannes ;

Schnerch, Dominik ;

Follo, Marie ;

Waesch, Ralph ;

Engelhardt, Monika .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (01) :104-116

[10] Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment [J].

Zago, Manola ;

Oehrlein, Katharina ;

Rendl, Corinna ;

Hahn-Ast, Corinna ;

Kanz, Lothar ;

Weisel, Katja .

ANNALS OF HEMATOLOGY, 2014, 93 (12) :1993-1999

← 1 →